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Relationships between plasma amino 
acid concentrations and blood pressure 
in South Africans of African descent 
ever, despite data to suggest that increasing the availability of 
arginine may reduce cardiovascular risk, there is little evidence to 
indicate that the availability of arginine as a substrate for NO is in 
fact abnormal.
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AMINO ACIDS AND 
BLOOD PRESSURE
INTRODUCTION                                                              
Despite considerable advances in treatment, cardiovascular disease 
remains a leading cause of death worldwide(1) consequently; 
improved methods of managing cardiovascular risk are required. 
An important change associated with vascular pathology is abnor-
malities of endothelial function and in this regard, changes in the 
capacity of endothelial cells to synthesise and release nitric oxide 
(NO) is a key alteration. Twenty years ago NO was identifi ed as 
an arterial vasodilator(2,3) formed from the semi-essential amino 
acid, L-arginine, in endothelial cells.(4) Although NO production 
depends on extracellular arginine,(5) the importance of arginine in 
cardiovascular diseases is derived mainly from studies showing 
benefi cial effects of supplementation. Indeed, arginine supple-
mentation decreases blood pressure (BP);(6) improves outcomes in 
patients with heart failure;(7) increases coronary small vessel 
endothelial function;(8) inhibits atherogenesis;(9,10) and improves 
hemodynamic responses in hypercholesterolemic men.(11) How-
Oral supplementation with the amino acid arginine, the 
precursor of the vasodilator nitric oxide (NO), is associated 
with a reduction in blood pressure (BP). However, it is 
uncertain whether a decreased plasma arginine concentra-
tion predicts increases in BP.  We assessed the relationship 
between fasting plasma arginine or other amino acid 
concentrations and 24 hour ambulatory BP in 75 never-
treated participants recruited from the Johannesburg area, 
55 of whom were male. Plasma amino acid concentrations 
were measured with high performance liquid chromato-
graphy-mass-spectrometry. Plasma arginine concentrations 
were not inversely correlated with ambulatory BP. How-
ever, plasma arginine concentrations were increased in 36 
participants with a mean daytime systolic BP >140 mm Hg 
(61 ± 17 μmol/L) as compared to the remaining partici-
pants (54 ± 15 μmol/L, p<0.05). Moreover, plasma arginine 
concentrations were positively correlated with 24-hour 
diastolic BP (r=0.26, p<0.05). In males with a BMI<30kg/m2, 
plasma arginine concentrations were positively correlated 
with both night diastolic (r=0.46, p<0.005) and systolic 
(r=0.42, p<0.005) BP. In a multivariate model with adjust-
ments for age gender, body mass index, and other amino 
acid concentrations, plasma arginine concentrations were 
independently and positively associated with night diastolic 
BP (p<0.05). In conclusion plasma arginine concentrations 
are positively associated with ambulatory BP in a group 
of participants of African descent in South Africa. These 
data do not support the notion that defi ciencies of arginine, 
the amino acid substrate for NO, are related to increases 
in BP in groups of African ancestry living in South Africa. 
However, as with other ethnic groups, the positive relation-
ship between plasma arginine concentrations and BP 
suggests a reduced capacity to utilise the amino acid 
substrate for NO synthesis. SAHeart 2009; 6:142-147
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Although it is thought that circulating arginine concentrations 
remain constant, low arginine concentrations do occur(12) and, in 
infectious diseases, where the inducible form of nitric oxide 
synthase (iNOS) would be active, these decreased concentrations 
are associated with adverse outcomes in diseases such as cerebral 
malaria.(13) With respect to cardiovascular diseases, some studies 
have assessed the relationship between plasma arginine concen-
trations and BP with outcomes that suggest that, although the 
availability of arginine is not reduced in hypertension, the capacity 
to produce NO from arginine may be impaired.(14-16) None of 
these studies were conducted in groups of African ancestry whom 
have a higher prevalence of hypertension than their Caucasian 
counterparts.(17) Consequently, the aim of the present study was 
to evaluate the relationship between plasma arginine or other 
amino acids and BP in a group of African descent living in Africa.
METHODS                                                                         
Study group and BP measurement
A convenience sample of apparently healthy adult South Africans 
of African ancestry (black South Africans) not receiving antihyper-
tensive or other therapy, and without cardiovascular disease were 
recruited from outpatient clinics at the Chris Hani-Baragwanath 
Hospital (participants were referred for screening of cardiovas-
cular disease); inner city clinics (also referred for screening of 
cardiovascular disease); and from laboratory staff at the National 
Health Laboratory Services at the Charlotte Maxeke (Johannes-
burg) Hospital. Participants provided written, informed consent. 
Ambulatory 24 hour BP measurements were obtained using 
oscillometric monitors (SpaceLabs, model 90207), programmed 
to measure BP at 20-minute intervals from 06:00 to 18:00h 
(daytime) and at 30-minute intervals from 18:00 to 06:00h 
(night time).  An increased day ambulatory BP was defi ned as ≥ 140 
or 90 mm Hg. Routine blood chemistry was performed by the 
National Health Laboratory Services.
Plasma amino acid measurements
After having fasted from 22:00 hours the previous night, early 
morning blood samples were obtained from participants and 
plasma was stored at -70oC. Concentrations of amino acids were 
determined using high performance liquid chromatography 
(HPLC)-mass spectrometry (MS) according to previously described 
techniques.(18,19) Quantifi cation of the amino acids was performed 
using an Agelient HPLC system using a Phenomenex Prodigy C18 
column (4.6x100mm; 3μm particle size) equilibrated with 25mM 
heptafl uorobutyric acid in water containing 5% acetonitrile and 
0.1% formic acid (Mobile phase A) at 45oC. Separation was 
achieved with a gradient of 25mM heptafl uorobutyric acid in 
acetonitrile containing 5% water and 0.1% formic acid. The 
gradient was as follows: 0-3 minutes: 100% A;  3-9.5 minutes: 
30% B; 9.5-13.5 minutes: 32% B; 13.5-14 minutes 60% B with a 
4 minutes re-equilibration step. A fl ow rate of 700μl/min was 
used and a 10μl injection volume. Eluting peaks were identifi ed 
by retention time and multiple reactions monitoring using a MSD 
Sciex 4000QTrap mass spectrometer in positive mode at 5200V.
Data analysis
Analysis was performed using SAS version 9.1 software. Results 
are reported as mean±SD or as frequencies. Either a Student’s 
t-test or a Kruskal-Wallis test was used to determine differences 
between groups for normally and non-normally distributed data 
respectively. Pearson’s correlation coeffi cients were used to 
determine the association between variables and multivariate 
regression analysis to assess the independent relationships be-
tween plasma arginine concentrations and BP.  Primary analysis was 
conducted in the whole group, but as the majority of participants 
were male, secondary analysis was performed in males only. As 
obesity may represent a nutritional abnormality that may alter 
plasma amino acid profi les, secondary analysis was also conducted 
in participants with a BMI<30 kg/m2. A p-value of less than 0.05 
was considered to be of statistical signifi cance.
RESULTS                                                                            
Participant characteristics
Table 1 shows the characteristics of the participants and the dif-
ferences in the characteristics of participants with a normal and 
increased day BP. The majority of participants were male (80%). 
The mean age of the participants was 49 and approximately 
one third had a history of regular smoking or use of alcohol. 
144
AMINO ACIDS AND BLOOD PRESSURE
TABLE 1:  Demographics of all study participants and comparison of demographic and clinical data between participants with normal and elevated 
ambulatory blood pressures (ABP).
SBP, systolic BP; DBP, diastolic BP; 24H, 24-hour ; BMI, body mass index.   *** p<0.0001 versus participants with mean day ABP < 140 or 90 mm Hg
 All participants Mean Day ABP  Mean Day ABP   Mean Day ABP  Mean Day ABP
 (n=75)  DBP<90mm Hg   DBP≥90mm Hg SBP<140mm Hg SBP≥140mm Hg
  (n=33) (n=42) (n=39) (n=36)
Male/female
Age (years)
BMI (kg/m2)
Smoking (n (ex-n))
Alcohol (n)
Mean Ambulatory BP
24H SBP/ (mm Hg)
24H DBP (mm Hg)
Day SBP/ (mm Hg)
Day DBP (mm Hg)
Night SBP/ (mm Hg)
Night DBP (mm Hg)
60/15
49 ± 7
27.8 ± 4.9
24 (8)
28
135 ± 18/
87 ± 11
139 ± 20/
92 ± 12
130 ± 17/
83 ± 12
24/9
50 ± 7
26.8 ± 4.7
11 (3)
12
121 ± 13/
78 ± 8
123 ± 12/
81 ± 7
119 ± 14/
75 ± 9
36/6
48 ± 6
28.5 ± 5.0 
13 (5)
16
146 ± 14/ ***
95 ± 8 ***
152 ± 15/ ***
101 ± 8 ***
140 ± 14 ***
90 ± 9 ***
24/9
50 ± 7
26.6 ± 4.9
11 (3)
12
121 ± 11/
80 ± 8
124 ± 11/
83 ± 8
119 ± 12/
76 ± 9
36/6
48 ± 7
28.9 ± 4.7 
13 (5)
16
150 ± 12/ ***
96 ± 8 ***
155 ± 13/ ***
102 ± 8 ***
143 ± 12 ***
91 ± 9 ***
TABLE 2:  Differences in amino acid concentrations (μmol/L) in participants with normal and elevated ambulatory blood pressures (ABP). Bold 
shows data that is different from participants with a normal day BP.
SBP, systolic BP, DBP, diastolic BP.    * =p<0.05 versus group with mean day ABP < 140 or 90 mm Hg 
 All subjects Mean Day ABP  Mean Day ABP   Mean Day ABP  Mean Day ABP
 (n=75)  DBP<90mm Hg   DBP≥90mm Hg SBP<140mm Hg SBP≥140mm Hg
  (n=33) (n=42) (n=39) (n=36)
Alanine
Arginine
Asparagine
Citrulline
Histidine
Isoleucine
Leucine
Lysine
Methionine
Ornithine
Phenylalanine
Proline
Serine
Taurine
Threonine
Tryptophan
Tyrosine
Valine
3-methylhistidine
177 ± 41
57 ± 16
23 ± 22
14 ± 7
40 ± 6
36 ± 10
69 ± 14
77 ± 19
11 ± 4
17 ± 15
35 ± 7
86 ± 94
9 ± 15
29 ± 18
59 ± 21
24 ± 6
22 ± 6
90 ± 19
5 ± 4
186 ± 42
56 ± 13
23 ±14
13 ± 4
41 ± 6
35 ± 9
67 ± 11
76 ± 18
12 ± 4
15 ± 12
34 ± 6
71 ± 16
13 ± 20
28 ± 18
61 ± 20
24 ± 6
22 ± 6
87 ± 17
5 ± 4
169 ± 38
58 ± 18
22 ± 27
15 ± 9
40 ± 6
37 ± 10
70 ± 16
78 ± 20
11 ± 4
18 ± 16
35 ± 7
97 ± 125
5 ± 6*
30 ± 18
57 ± 22
24 ± 6
22 ± 6
93 ± 20
4 ± 3
181 ± 42
54 ± 15
21 ±13
13 ± 4
41 ± 6
35 ± 9
67 ± 12
74 ± 19
12 ± 4
17 ± 13
34 ± 7
69 ± 18
11 ± 18
28 ± 18
60 ± 22
23 ± 6
22 ± 6
88 ± 18
5 ± 4
172 ± 39
61 ± 17*
24 ± 29
17 ± 10
40 ± 6
37 ± 10
70 ± 16
81 ± 19
11 ± 3
17 ± 16
35 ± 6
103 ± 133
6 ± 6
31 ± 18
57 ± 20
25 ± 6
22 ± 5
93 ± 20
4 ± 3
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No signifi cant differences were noted in the characteristics of 
the participants with and without an increased day BP except for 
higher BP values noted in those with increased day BP values.
Plasma amino acid profi les in participants
Table 2 shows the amino acid profi les in all participants and the 
differences in amino acid profi les of participants with a normal 
versus increased day BP.  A lower plasma serine concentration was 
noted in participants with elevated day diastolic BP values. More-
over, an increased plasma arginine concentration was noted in 
participants with an increased day systolic BP.
Relationship between plasma amino acid concentrations and 
ambulatory BP
Table 3 shows the Pearson’s correlation coeffi cients between 
plasma arginine and lysine concentrations and ambulatory BP. 
Plasma arginine concentrations were positively correlated with 
ambulatory BP in the whole group and in secondary analyses in 
males and non-obese participants. Plasma concentrations of lysine, 
an amino acid using the same membrane transporter as arginine, 
also correlated with ambulatory BP in non-obese males. In all 
participants, two other amino acids showed statistically signifi cant 
correlations with BP.  In this regard, plasma alanine concentrations 
correlated negatively with mean day systolic BP (r=-0.23, p<0.05) 
and plasma serine concentrations correlated negatively with mean 
day diastolic BP (r=-0.25, p=0.046). Plasma serine, but not alanine 
concentrations, remained signifi cantly and inversely correlated 
with both mean daytime systolic (r=-0.42, p=0.007) and diastolic 
(r=-0.43, p=0.006) BP in males with a BMI<30kg/m2. 
Factors associated with ambulatory BP in multivariate 
regression models
In a multivariate model with age gender, body mass index, argi-
nine, alanine, proline and serine included in the model, only male 
gender (p<0.05) and plasma arginine concentrations (p<0.05) 
were independently associated with night diastolic BP. When 
including lysine in a regression model with arginine, lysine replaced 
arginine as being a signifi cant predictor of mean night diastolic BP.
DISCUSSION                                                                     
The main fi nding of the present study is that plasma concentra-
tions of the NO precursor, L-arginine, are positively associated 
with night diastolic BP in a group of 75 participants of African 
descent in Africa and that this association remained after adjust-
ments for potential confounders in addition to the plasma 
concentrations of other amino acids. This positive association 
between plasma arginine concentrations and night diastolic BP 
was similarly observed in secondary analysis in the predominant 
gender (male) in the study group and in participants whom were 
not obese.
TABLE 3:  Pearson correlation coeffi cients between fasting plasma arginine and lysine concentrations and ambulatory blood pressures. Bold indicates 
signifi cant correlations.
SBP, systolic BP; DBP, diastolic BP; 24H, 24-hour.    * p<0.05, ** p<0.005
 All participants BMI<30kg/m2  Males   Males    Mean Day ABP
 (n=75)    (n=55) (n=60) BMI<30kg/m2 BMI<30kg/m2
    (n=46) (n=46)
Mean Ambulatory BP
24H SBP/ (mm Hg)
24H DBP (mm Hg)
Day SBP/ (mm Hg)
Day DBP (mm Hg)
Night SBP/ (mm Hg)
Night DBP (mm Hg)
0.16
  0.26*
0.16
0.22
0.16
 0.28*
0.26
0.23
0.27*
0.33*
0.27*
0.36*
0.23
 0.32*
0.20
 0.27*
0.25
  0.36**
0.31*
 0.37*
0.26
 0.30*
 0.35*
  0.45**
0.32*
0.31*
0.25
0.21
  0.42**
   0.46**
 Arginine  Lysine
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correlated with plasma arginine concentrations as arginine and 
lysine depend on the same membrane transporter. This relation-
ship may explain the ability of plasma lysine to replace plasma 
arginine concentrations as independent predictors of BP in 
multivariate regression analysis.
The results of the present study need to be interpreted in the 
context of the study limitations. In this regard, the present study 
was conducted in a study sample with a high proportion of men 
(80%). Hence, the outcomes may refl ect a gender-specifi c effect. 
Second, the present study was performed in a convenience sample 
and hence further studies are required in a larger study sample 
of randomly recruited participants. Third, the present study was 
a cross-sectional study and hence further studies are required 
to establish a temporal relationship between plasma arginine 
concentrations and ambulatory BP. Last, we did not measure 
membrane transport of arginine or NO production from cells 
in participants and hence we could not provide an explanation 
for the positive relationship between plasma arginine concentra-
tions and BP.
In conclusion, a positive relationship between plasma arginine 
concentrations and ambulatory BP occurs in people of African 
origins. These data support the notion(14-16) that although increases 
in BP are unlikely to be attributed to a decreased availability of 
arginine, increases in BP may occur because of a defi ciency in 
arginine uptake resulting in a reduced synthesis of NO.
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The results of the present study conducted in a group of African 
descent in Africa, concur with two studies conducted in Caucasian 
groups with a case-control study design showing that plasma 
arginine concentrations are increased in hypertensive patients.(14,15) 
In this regard however, in one study,(14) plasma samples were 
obtained in 36 normotensive controls and 34 hypertensives 
whilst these patients were still on therapy. Therefore, whether 
the results of this prior study(14) represent an impact of treat-
ment or the presence of hypertension is uncertain. In the other 
study, plasma arginine concentrations were shown to be increased 
in 36 never-treated hypertensives as compared to only 8 control 
participants.(15) It may be argued that these data refl ect a false 
positive outcome as the study sample of control participants was 
very small. The results of the present study therefore add to 
these prior studies as the analyses performed was conducted using 
a continuous (regression analysis) together with a case-control 
approach, the study sample size of never-treated participants 
(n=75) was considerably larger than prior studies, and ambulatory 
BP was performed to improve the sensitivity of the analysis.
The positive association between plasma arginine concentrations 
and BP in the present study requires an explanation. In this regard 
it is unlikely to refl ect cause and effect as extracellular arginine is 
required for NO production(5) and consequently vasodilatation(19,20) 
a change that will decrease and not increase BP. Moreover, 
supplementation with dietary arginine decreases BP in hyper-
tension.(6) It is possible that the positive relationship between 
plasma arginine concentrations and BP may refl ect a reduced 
capacity for the cellular uptake of arginine as previously 
suggested,(14,15) a change which would increase plasma arginine 
concentrations whilst at the same time reduce the capacity for 
NO synthesis.
We are unable to provide an explanation for either the lower 
plasma serine concentrations in participants with an elevated BP 
or the positive relationship between plasma lysine concentrations 
and ambulatory BP in males with a BMI <30 kg/m2. However, 
studies conducted in a genetic animal model of hypertension(21) 
have similarly reported decreased serine concentrations in hyper-
tension. Moreover, plasma lysine concentrations may be closely 
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